hydroxychloroquine has been researched along with Acute Respiratory Distress Syndrome in 27 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties." | 5.56 | Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. ( Airó, P; Andreoli, L; Bertasi, V; Bianchi, M; Bottone, D; Brucato, A; Civelli, P; Colombo, E; Cotelli, MS; Damiolini, E; Franceschini, F; Furloni, R; Galbassini, G; Gatta, D; Ghirardelli, ML; Magri, R; Malamani, P; Mendeni, M; Miclini, M; Molinari, S; Morotti, A; Piantoni, S; Richini, D; Salada, L; Scarsi, M; Tincani, A; Turla, M; Vender, A, 2020) |
| " In fact, two of the actually used drugs against SARS-CoV2, such as chloroquine and the combination lopinavir/ritonavir, might determine a QT (the time from the start of the Q wave to the end of the T wave) interval prolongation and they show several interactions with antiarrhythmic drugs and antipsychotic medications, making them prone to an increased risk of developing arrhythmias." | 5.12 | COVID-19 and the burning issue of drug interaction: never forget the ECG. ( Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S, 2021) |
| "COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major public health crisis threatening humanity at this point in time." | 2.66 | COVID-19 in Children: Clinical Approach and Management. ( Dhochak, N; Kabra, SK; Lodha, R; Sankar, J, 2020) |
| "We treated two patients with severe respiratory failure due to coronavirus disease 2019 (COVID-19)." | 2.66 | High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19. ( Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T, 2020) |
| "KEY POINTS: • COVID19 studies show higher mortality in men, due to severe pneumonia and ARDS, indicating possible X-linked mediated differences • G6PD, the most common X-linked enzymopathy, highly prevalent in African Americans and Italians, maintains redox homeostasis." | 1.62 | G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg? ( Ensor, J; Iyer, SP; Padmanabhan, S; Pingali, SR; Sahay, S; Youssef, G; Youssef, JG; Zahiruddin, F; Zu, Y, 2021) |
| "The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release." | 1.56 | COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. ( Dai, SM; Tong, Q; Zhou, D, 2020) |
| "Eight percent died and 5% developed acute respiratory distress syndrome (ARDS)." | 1.56 | A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. ( Affatato, S; Alberici, F; Boni, F; Bossini, N; Bove, S; Bracchi, M; Calcaterra, E; Camerini, C; Cortinovis, R; Costantino, EM; Delbarba, E; Econimo, L; Gaggia, P; Gaggiotti, M; Gallico, A; Guerini, A; Lucca, B; Maffei, C; Manenti, C; Movilli, E; Mucchetti, A; Pezzini, E; Piarulli, P; Pola, A; Possenti, S; Saccà, C; Scolari, F; Terlizzi, V; Valerio, F; Zappa, M; Zubani, R, 2020) |
| "Hydroxychloroquine (HCQ) has its own side effects, some of which are very serious like acute haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients." | 1.56 | A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. ( Clevenbergh, P; De Bels, D; Leemans, S; Mahadeb, B; Maillart, E; Salaouatchi, MT; Van Noten, H; Vandergraesen, T, 2020) |
| "Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties." | 1.56 | Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. ( Airó, P; Andreoli, L; Bertasi, V; Bianchi, M; Bottone, D; Brucato, A; Civelli, P; Colombo, E; Cotelli, MS; Damiolini, E; Franceschini, F; Furloni, R; Galbassini, G; Gatta, D; Ghirardelli, ML; Magri, R; Malamani, P; Mendeni, M; Miclini, M; Molinari, S; Morotti, A; Piantoni, S; Richini, D; Salada, L; Scarsi, M; Tincani, A; Turla, M; Vender, A, 2020) |
| "It may cause severe viral pneumonia with Acute Respiratory Distress Syndrome requiring critical care." | 1.56 | Very severe COVID-19 in the critically ill in Tunisia. ( Boussarsar, M; Ennouri, E; Jerbi, S; Mahmoud, J; Meddeb, K; Nachi, R; Saida, IB; Thabet, N, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 1 (3.70) | 24.3611 |
| 2020's | 25 (92.59) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, D | 1 |
| Dai, SM | 1 |
| Tong, Q | 1 |
| Marotto, D | 1 |
| Sarzi-Puttini, P | 1 |
| Lipworth, B | 1 |
| Chan, R | 1 |
| Lipworth, S | 1 |
| RuiWen Kuo, C | 1 |
| Sankar, J | 1 |
| Dhochak, N | 1 |
| Kabra, SK | 1 |
| Lodha, R | 1 |
| Rahmanzade, R | 1 |
| Rahmanzadeh, R | 1 |
| Hashemian, SM | 1 |
| Aouba, A | 1 |
| Baldolli, A | 1 |
| Geffray, L | 1 |
| Verdon, R | 1 |
| Bergot, E | 1 |
| Martin-Silva, N | 1 |
| Justet, A | 1 |
| Douedi, S | 1 |
| Miskoff, J | 1 |
| Bozzalla Cassione, E | 1 |
| Zanframundo, G | 1 |
| Biglia, A | 1 |
| Codullo, V | 1 |
| Montecucco, C | 1 |
| Cavagna, L | 1 |
| Alberici, F | 1 |
| Delbarba, E | 1 |
| Manenti, C | 1 |
| Econimo, L | 1 |
| Valerio, F | 1 |
| Pola, A | 1 |
| Maffei, C | 1 |
| Possenti, S | 1 |
| Lucca, B | 1 |
| Cortinovis, R | 1 |
| Terlizzi, V | 1 |
| Zappa, M | 1 |
| Saccà, C | 1 |
| Pezzini, E | 1 |
| Calcaterra, E | 1 |
| Piarulli, P | 1 |
| Guerini, A | 1 |
| Boni, F | 1 |
| Gallico, A | 1 |
| Mucchetti, A | 1 |
| Affatato, S | 1 |
| Bove, S | 1 |
| Bracchi, M | 1 |
| Costantino, EM | 1 |
| Zubani, R | 1 |
| Camerini, C | 1 |
| Gaggia, P | 1 |
| Movilli, E | 1 |
| Bossini, N | 1 |
| Gaggiotti, M | 1 |
| Scolari, F | 1 |
| Maillart, E | 1 |
| Leemans, S | 1 |
| Van Noten, H | 1 |
| Vandergraesen, T | 1 |
| Mahadeb, B | 1 |
| Salaouatchi, MT | 1 |
| De Bels, D | 1 |
| Clevenbergh, P | 1 |
| Nasir, N | 1 |
| Farooqi, J | 1 |
| Mahmood, SF | 1 |
| Jabeen, K | 1 |
| Iannaccone, G | 1 |
| Scacciavillani, R | 1 |
| Del Buono, MG | 1 |
| Camilli, M | 1 |
| Ronco, C | 1 |
| Lavie, CJ | 1 |
| Abbate, A | 1 |
| Crea, F | 1 |
| Massetti, M | 1 |
| Aspromonte, N | 1 |
| Massabeti, R | 1 |
| Cipriani, MS | 1 |
| Valenti, I | 1 |
| Colafrancesco, S | 1 |
| Scrivo, R | 1 |
| Barbati, C | 1 |
| Conti, F | 1 |
| Priori, R | 1 |
| Ghodsizad, A | 1 |
| Grant, AA | 1 |
| Mirsaeidi, M | 1 |
| Sneij, WC | 1 |
| Khalid, L | 1 |
| Delazerda, D | 1 |
| Auerbach, JS | 1 |
| Alvarez, RA | 1 |
| de Marchena, EJ | 1 |
| Hare, J | 1 |
| Guerra, G | 1 |
| Vianna, R | 1 |
| Loebe, M | 1 |
| Scarsi, M | 1 |
| Piantoni, S | 1 |
| Colombo, E | 1 |
| Airó, P | 1 |
| Richini, D | 1 |
| Miclini, M | 1 |
| Bertasi, V | 1 |
| Bianchi, M | 1 |
| Bottone, D | 1 |
| Civelli, P | 1 |
| Cotelli, MS | 1 |
| Damiolini, E | 1 |
| Galbassini, G | 1 |
| Gatta, D | 1 |
| Ghirardelli, ML | 1 |
| Magri, R | 1 |
| Malamani, P | 1 |
| Mendeni, M | 1 |
| Molinari, S | 1 |
| Morotti, A | 1 |
| Salada, L | 1 |
| Turla, M | 1 |
| Vender, A | 1 |
| Tincani, A | 1 |
| Brucato, A | 1 |
| Franceschini, F | 1 |
| Furloni, R | 1 |
| Andreoli, L | 1 |
| Sciaccaluga, C | 1 |
| Cameli, M | 1 |
| Menci, D | 1 |
| Mandoli, GE | 1 |
| Sisti, N | 1 |
| Cameli, P | 1 |
| Franchi, F | 1 |
| Mondillo, S | 1 |
| Valente, S | 1 |
| Fujii, H | 1 |
| Tsuji, T | 1 |
| Yuba, T | 1 |
| Tanaka, S | 1 |
| Suga, Y | 1 |
| Matsuyama, A | 1 |
| Omura, A | 1 |
| Shiotsu, S | 1 |
| Takumi, C | 1 |
| Ono, S | 1 |
| Horiguchi, M | 1 |
| Hiraoka, N | 1 |
| Bartoletti, M | 1 |
| Marconi, L | 1 |
| Scudeller, L | 1 |
| Pancaldi, L | 1 |
| Tedeschi, S | 1 |
| Giannella, M | 1 |
| Rinaldi, M | 1 |
| Bussini, L | 1 |
| Valentini, I | 1 |
| Ferravante, AF | 1 |
| Potalivo, A | 1 |
| Marchionni, E | 1 |
| Fornaro, G | 1 |
| Pascale, R | 1 |
| Pasquini, Z | 1 |
| Puoti, M | 1 |
| Merli, M | 1 |
| Barchiesi, F | 1 |
| Volpato, F | 1 |
| Rubin, A | 1 |
| Saracino, A | 1 |
| Tonetti, T | 1 |
| Gaibani, P | 1 |
| Ranieri, VM | 1 |
| Viale, P | 1 |
| Cristini, F | 1 |
| Saida, IB | 1 |
| Ennouri, E | 1 |
| Nachi, R | 1 |
| Meddeb, K | 1 |
| Mahmoud, J | 1 |
| Thabet, N | 1 |
| Jerbi, S | 1 |
| Boussarsar, M | 1 |
| Rodriguez-Gonzalez, CG | 1 |
| Chamorro-de-Vega, E | 1 |
| Valerio, M | 1 |
| Amor-Garcia, MA | 1 |
| Tejerina, F | 1 |
| Sancho-Gonzalez, M | 1 |
| Narrillos-Moraza, A | 1 |
| Gimenez-Manzorro, A | 1 |
| Manrique-Rodriguez, S | 1 |
| Machado, M | 1 |
| Olmedo, M | 1 |
| Escudero-Vilaplana, V | 1 |
| Villanueva-Bueno, C | 1 |
| Torroba-Sanz, B | 1 |
| Melgarejo-Ortuño, A | 1 |
| Vicente-Valor, J | 1 |
| Herranz, A | 1 |
| Bouza, E | 1 |
| Muñoz, P | 1 |
| Sanjurjo, M | 1 |
| Gomes, CP | 1 |
| Fernandes, DE | 1 |
| Casimiro, F | 1 |
| da Mata, GF | 1 |
| Passos, MT | 1 |
| Varela, P | 1 |
| Mastroianni-Kirsztajn, G | 1 |
| Pesquero, JB | 1 |
| Youssef, JG | 1 |
| Zahiruddin, F | 1 |
| Youssef, G | 1 |
| Padmanabhan, S | 1 |
| Ensor, J | 1 |
| Pingali, SR | 1 |
| Zu, Y | 1 |
| Sahay, S | 1 |
| Iyer, SP | 1 |
| JamaliMoghadamSiahkali, S | 1 |
| Zarezade, B | 1 |
| Koolaji, S | 1 |
| SeyedAlinaghi, S | 1 |
| Zendehdel, A | 1 |
| Tabarestani, M | 1 |
| Sekhavati Moghadam, E | 1 |
| Abbasian, L | 1 |
| Dehghan Manshadi, SA | 1 |
| Salehi, M | 1 |
| Hasannezhad, M | 1 |
| Ghaderkhani, S | 1 |
| Meidani, M | 1 |
| Salahshour, F | 1 |
| Jafari, F | 1 |
| Manafi, N | 1 |
| Ghiasvand, F | 1 |
| Alser, O | 1 |
| Mokhtari, A | 1 |
| Naar, L | 1 |
| Langeveld, K | 1 |
| Breen, KA | 1 |
| El Moheb, M | 1 |
| Kapoen, C | 1 |
| Gaitanidis, A | 1 |
| Christensen, MA | 1 |
| Maurer, LR | 1 |
| Mashbari, H | 1 |
| Bankhead-Kendall, B | 1 |
| Parks, J | 1 |
| Fawley, J | 1 |
| Saillant, N | 1 |
| Mendoza, A | 1 |
| Paranjape, C | 1 |
| Fagenholz, P | 1 |
| King, D | 1 |
| Lee, J | 1 |
| Farhat, MR | 1 |
| Velmahos, GC | 1 |
| Kaafarani, HMA | 1 |
| Arıkan-Ayyıldız, Z | 1 |
| Caglayan-Sozmen, S | 1 |
| Isık, S | 1 |
| Deterding, R | 1 |
| Dishop, MK | 1 |
| Couderc, R | 1 |
| Epaud, R | 1 |
| Louha, M | 1 |
| Uzuner, N | 1 |
| Maddison, PJ | 1 |
| Thorpe, C | 1 |
| Seale, JR | 1 |
| Ahmed, W | 1 |
| Whiteley, GS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh[NCT04434144] | 116 participants (Actual) | Observational [Patient Registry] | 2020-05-02 | Completed | |||
| An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults[NCT05808231] | 100 participants (Anticipated) | Interventional | 2021-04-26 | Recruiting | |||
| Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)[NCT04627467] | Phase 2 | 3,217 participants (Actual) | Interventional | 2020-03-28 | Completed | ||
| A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics[NCT04353271] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2020-04-17 | Terminated (stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias) | ||
| Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial[NCT04397328] | Phase 3 | 336 participants (Anticipated) | Interventional | 2020-05-19 | Not yet recruiting | ||
| Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial[NCT04491994] | Phase 3 | 540 participants (Actual) | Interventional | 2020-04-10 | Completed | ||
| Diagnosis of Invasive Pulmonary Aspergillosis (IPA) - Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid in Patients With and Without COVID-19[NCT04848831] | 100 participants (Anticipated) | Observational | 2021-06-01 | Not yet recruiting | |||
| Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19[NCT04667780] | Phase 3 | 102 participants (Actual) | Interventional | 2020-12-01 | Completed | ||
| Non-ventilated Prone Positioning in the COVID-19 Population[NCT05957588] | 216 participants (Actual) | Interventional | 2021-10-01 | Completed | |||
| Hydroxychloroquine in Pediatric ILD With Genetic Surfactant Dysfunction Disorders: Cross-control, Prospective Study[NCT03822780] | 25 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial
| Intervention | participants (Number) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 1 |
Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Control | 2 |
After start of treatment, development of fever > 101 F for > 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC < 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status (NCT04491994)
Timeframe: 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care (SOC) | 5 |
| Intervention Group | 11 |
6 reviews available for hydroxychloroquine and Acute Respiratory Distress Syndrome
| Article | Year |
|---|---|
COVID-19 in Children: Clinical Approach and Management.
Topics: Acute Lung Injury; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Clinical Laboratory T | 2020 |
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Betacoronavirus; CCR5 Receptor Antagonis | 2020 |
Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.
Topics: Adaptive Immunity; Adult; Anticoagulants; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; C | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral | 2021 |
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus | 2020 |
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics.
Topics: Acute Kidney Injury; Amantadine; Angiotensin-Converting Enzyme 2; Cathepsin L; Chloroquine; COVID-19 | 2020 |
1 trial available for hydroxychloroquine and Acute Respiratory Distress Syndrome
| Article | Year |
|---|---|
Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.
Topics: Antiviral Agents; Ascorbic Acid; Body Temperature; COVID-19 Drug Treatment; Female; Humans; Hydroxyc | 2021 |
20 other studies available for hydroxychloroquine and Acute Respiratory Distress Syndrome
| Article | Year |
|---|---|
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
What is the role of rheumatologists in the era of COVID-19?
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimalarials; Azetidines; Betacoronavir | 2020 |
Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Angiotensin-Converting Enzyme Inhi | 2020 |
Respiratory Distress in Postanesthesia Care Unit: First Presentation of Coronavirus Disease 2019 in a 17-Year-Old Girl: A Case Report.
Topics: Adolescent; Airway Extubation; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus; Coronav | 2020 |
Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Betacoronavirus; C-Reactive Protein; Coronav | 2020 |
Novel coronavirus 2019 (COVID-19): A case report and review of treatments.
Topics: Adenosine Monophosphate; Aged; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Clinical L | 2020 |
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Azathioprine; Betacoronavirus; Clinical Labora | 2020 |
A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection.
Topics: Aged; Aged, 80 and over; Antimalarials; Antiviral Agents; Coronavirus Infections; COVID-19; Female; | 2020 |
A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
Topics: Aged; Azithromycin; Betacoronavirus; Blood Transfusion; Continuous Renal Replacement Therapy; Corona | 2020 |
COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan.
Topics: Aged; Aged, 80 and over; Azithromycin; Coronavirus Infections; COVID-19; Diabetes Complications; Fem | 2020 |
Covid-19: A systemic disease treated with a wide-ranging approach: A case report.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Azithromycin; China; Coronavirus Infecti | 2020 |
Management of crash and burn patients with SARS-CoV-2 associated ARDS.
Topics: Adult Stem Cells; Angiotensin-Converting Enzyme 2; Azithromycin; Blood Component Transfusion; COVID- | 2020 |
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Case-Control S | 2020 |
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical | 2021 |
Very severe COVID-19 in the critically ill in Tunisia.
Topics: Antiviral Agents; Betacoronavirus; Cardiovascular Diseases; Comorbidity; Coronavirus Infections; COV | 2020 |
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antiviral Agents; Comorbidity; CO | 2021 |
G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?
Topics: Black or African American; Contraindications, Drug; COVID-19; COVID-19 Nucleic Acid Testing; Critica | 2021 |
Multisystem outcomes and predictors of mortality in critically ill patients with COVID-19: Demographics and disease acuity matter more than comorbidities or treatment modalities.
Topics: Acute Kidney Injury; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Boston; Comorbidity | 2021 |
Survival of an infant with homozygous surfactant protein C (SFTPC) mutation.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Consanguinity; Genes, Recessive; Homo | 2014 |
'Catastrophic' antiphospholipid syndrome.
Topics: Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; Antirheumatic Agents; Critical | 2000 |